CTSK (Cathepsin K) is a gene encoding a member of the papain family of cysteine proteases with remarkable collagenolytic activity. Cathepsin K is uniquely capable of degrading native type I collagen, the predominant protein in bone matrix, making it the principal enzyme responsible for bone resorption by osteoclasts. Beyond its established role in skeletal biology, emerging research reveals that CTSK is expressed in various tissues including the brain, where it participates in extracellular matrix remodeling, protein aggregate clearance, and neuroinflammatory processes relevant to neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and multiple sclerosis["@bromme1999"][@gelb1996].
CTSK (Cathepsin K) is a gene encoding a member of the papain family of cysteine proteases with remarkable collagenolytic activity. Cathepsin K is uniquely capable of degrading native type I collagen, the predominant protein in bone matrix, making it the principal enzyme responsible for bone resorption by osteoclasts. Beyond its established role in skeletal biology, emerging research reveals that CTSK is expressed in various tissues including the brain, where it participates in extracellular matrix remodeling, protein aggregate clearance, and neuroinflammatory processes relevant to neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and multiple sclerosis["@bromme1999"][@gelb1996].
The CTSK gene is located on chromosome 1q21.3 and encodes a preproenzyme consisting of 329 amino acids that undergoes proteolytic processing to generate the mature, active enzyme. Cathepsin K possesses a characteristic papain-like fold with a catalytic dyad consisting of Cys25 and His159. The enzyme exhibits optimal activity at acidic pH (5.5-6.5), consistent with its function in lysosomal compartments and the resorption lacunae beneath osteoclasts["@drake2001"][@bromme1999].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cathepsin K</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CTSK</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cathepsin K</td></tr>
<tr><td><strong>Chromosome</strong></td><td>1q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1513](https://www.ncbi.nlm.nih.gov/gene/1513)</td></tr>
<tr><td><strong>OMIM</strong></td><td>601105</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000136754</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P43235](https://www.uniprot.org/uniprot/P43235)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Pycnodysostosis](/diseases/pycnodysostosis), [Osteoporosis](/diseases/osteoporosis), [Multiple Sclerosis](/diseases/multiple-sclerosis)</td></tr>
</table>
</div>
Cathepsin K is a member of the C1 family of cysteine proteases, sharing structural homology with other cathepsins (B, L, S, F). The mature enzyme consists of:
Cathepsin K exhibits distinctive substrate specificity, with a preference for collagen triple-helical sequences and elastin. This unique specificity arises from an extended S2 pocket that accommodates bulky hydrophobic residues and an occlusal loop that facilitates collagen binding[@bromme1999][@drake2001].
CTSK expression is tightly regulated by multiple factors:
Cathepsin K is predominantly expressed in:
Biallelic loss-of-function mutations in CTSK cause Pycnodysostosis (OMIM 265800), a rare autosomal recessive osteochondrodysplasia characterized by:
Cathepsin K represents a prime therapeutic target for [osteoporosis](/diseases/osteoporosis). The enzyme's unique ability to degrade type I collagen makes it essential for osteoclast-mediated bone resorption. Several cathepsin K inhibitors have been developed:
| Drug | Company | Development Status | Notes |
|------|---------|--------------------| ------|
| Odanacatib (MK-0822) | Merck | Discontinued | Excellent efficacy but stroke risk |
| MIV-711 | Medivir | Phase II | Reduced bone resorption markers |
| Relacatib | GlaxoSmithKline | Discontinued | Selectivity issues |
These inhibitors demonstrated significant reductions in bone resorption markers and fracture risk in clinical trials, though development was discontinued due to safety concerns with odanacatib (increased risk of stroke and cardiovascular events)[@drake2001][@ross2013][@yang2018].
Cathepsin K is increasingly recognized as playing complex roles in [Alzheimer's Disease](/diseases/alzheimers-disease) pathogenesis:
The relationship between CTSK and AD pathology remains complex:
In [Parkinson's Disease](/diseases/parkinsons-disease), cathepsin K may play both protective and pathogenic roles:
Cathepsin K contributes to [multiple sclerosis](/dieses/multiple-sclerosis) pathogenesis through multiple mechanisms:
In the central nervous system, cathepsin K is expressed in:
Outside the brain, CTSK is expressed at high levels in:
Given the complex role of CTSK in neurodegeneration, several therapeutic strategies are being explored:
Existing cathepsin K inhibitors developed for osteoporosis may be repurposed for neurodegenerative diseases:
CTSK inhibition may provide benefits when combined with:
Gelb and colleagues identified CTSK as the gene mutated in pycnodysostosis, establishing the first direct link between cathepsin K deficiency and human disease. This discovery provided crucial insights into the enzyme's role in bone metabolism and established CTSK as a therapeutic target[@gelb1996].
Bromme and colleagues characterized cathepsin K's unique substrate specificity, demonstrating its ability to degrade native collagen at neutral pH. This property distinguishes CTSK from other cathepsins and explains its critical role in bone resorption[@bromme1999].
The development of odanacatib demonstrated that cathepsin K inhibition could significantly reduce bone resorption and fracture risk in postmenopausal women, establishing the validity of this approach despite later safety concerns[@drake2001][@ross2013].
Burek and colleagues first characterized CTSK expression in AD brain, demonstrating elevated levels in microglia surrounding plaques and suggesting roles in amyloid clearance and neuroinflammation[@bureaus2009].